Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $35.77, for a total value of $7,154,000.00. Following the completion of the sale, the chief executive officer directly owned 1,599,154 shares of the company’s stock, valued at approximately $57,201,738.58. The trade was a 11.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $34.95, for a total transaction of $6,990,000.00.
• On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00.

Roivant Sciences Price Performance

ROIV stock traded down $0.12 during trading hours on Tuesday, reaching $34.52. The stock had a trading volume of 6,905,942 shares, compared to its average volume of 7,667,241. The stock has a market capitalization of $24.93 billion, a PE ratio of -65.13 and a beta of 1.12. The stock has a 50-day simple moving average of $35.27 and a 200 day simple moving average of $31.04. Roivant Sciences Ltd. has a fifty-two week low of $11.94 and a fifty-two week high of $37.97.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. On average, sell-side analysts forecast that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ROIV. Jefferies Financial Group Inc. acquired a new stake in Roivant Sciences during the 4th quarter worth approximately $76,272,000. Nicholas Investment Partners LP grew its holdings in Roivant Sciences by 13.9% in the 4th quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock valued at $6,073,000 after buying an additional 34,235 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Roivant Sciences in the 1st quarter valued at $3,957,000. Baader Bank Aktiengesellschaft bought a new position in Roivant Sciences during the 4th quarter worth $1,029,000. Finally, Bank of America Corp DE increased its position in Roivant Sciences by 8.0% during the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after buying an additional 235,493 shares during the period. 64.76% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ROIV. HC Wainwright reissued a “buy” rating and set a $41.00 price target on shares of Roivant Sciences in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research note on Thursday, August 6th. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Finally, Guggenheim increased their price target on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.